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We compared the activities of tedizolid to those of linezolid and other commonly used an-
timicrobial agents against gram-positive cocci recovered from patients with skin and skin 
structure infections (SSSIs) and hospital-acquired pneumonia (HAP) in Korean hospitals. 
Gram-positive isolates were collected from 356 patients with SSSIs and 144 patients with 
HAP at eight hospitals in Korea from 2011 to 2014. SSSIs included impetigo, cellulitis, 
erysipelas, furuncles, abscesses, and infected burns. Antimicrobial susceptibility was 
tested by using the CLSI agar dilution method. All of the gram-positive isolates were inhib-
ited by ≤1 μg/mL tedizolid. The minimum inhibitory concentration [MIC]90 of tedizolid was 
0.5 μg/mL for methicillin-resistant Staphylococcus aureus, which was 4-fold lower than 
that of linezolid. Tedizolid may become a useful option for the treatment of SSSIs and HAP 
caused by gram-positive bacteria.
Key Words: Tedizolid, Skin, Soft tissue, Infection, Pneumonia, Gram-positive bacteria 
Received: December 26, 2014
Revision received: February 2, 2015
Accepted: June 3, 2015
Corresponding author: Kyungwon Lee
Department of Laboratory Medicine, 
Research Institute of Bacterial Resistance, 
Yonsei University College of Medicine,  





© The Korean Society for Laboratory Medicine
This is an Open Access article distributed under 
the terms of the Creative Commons Attribution 
Non-Commercial License (http://creativecom-
mons.org/licenses/by-nc/3.0) which permits 
unrestricted non-commercial use, distribution, 
and reproduction in any medium, provided the 
original work is properly cited.
Skin and skin structure infections (SSSIs) are common prob-
lems in both inpatients and outpatients. The vast majority of SS-
SIs are caused by gram-positive organisms that are normal flora 
on the skin of human beings. Staphylococci and streptococci 
cause majority of gram-positive infections [1]. A recent increase 
in staphylococcal infections caused by methicillin-resistant 
Staphylococcus aureus (MRSA) has resulted in a significant in-
crease of cases of MRSA pneumonia in the health care setting, 
especially in the chronically ill population [2]. Vancomycin has 
been the cornerstone of treatment for MRSA infections. How-
ever, recently, vancomycin-resistant S. aureus and linezolid-re-
sistant Staphylococcus strains have emerged [3-5]. These 
strains pose significant challenges to the clinical treatment of in-
fections caused by these organisms. Tedizolid offers broad in vi-
tro activity against gram-positive pathogens, including MRSA 
and strains resistant to vancomycin or linezolid, and has greater 
potency than other drugs of its class [6, 7]. It was specifically 
designed to be active against linezolid-resistant S. aureus, in-
cluding strains containing the multidrug-resistant cfr gene [8].
 Tedizolid phosphate was recently approved by the U.S. Food 
and Drug Administration to treat patients with acute bacterial 
SSSI caused by S. aureus, various Streptococcus species, and 
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Enterococcus. In addition, planned studies will investigate the 
potential role of tedizolid in the treatment of community-ac-
quired bacterial pneumonia and hospital-acquired pneumonia 
(HAP) [9]. We published a previous report focusing on the ac-
tivity of tedizolid against collections of clinical isolates in a single 
institution, but it was not characterized by infection type [10]. 
Therefore, the present study aimed to compare the activities of 
tedizolid to those of linezolid and other commonly used antimi-
crobial agents against gram-positive cocci recovered from pa-
tients with SSSIs and HAP in Korean hospitals. 
 Non-duplicated aerobic and anaerobic gram-positive isolates 
were collected from clinical specimens of 356 patients with SS-
SIs and 144 patients with HAP at eight hospitals in Seoul and 
Gyeonggi province, Korea from 2011 to 2014. SSSIs included 
impetigo, cellulitis, erysipelas, furuncles, abscesses, and in-
fected burns [1, 11]. HAP was defined as pneumonia that oc-
curred 48 hr or more after admission.
 Species were identified by using conventional methods or the 
Vitek 2 system (bioMérieux, Marcy l’Etolile, France). Antimicro-
bial susceptibility was tested by using the CLSI agar dilution 
method [12, 13]. Mueller-Hinton agar was used as a growth 
medium (Becton Dickinson, Cockeysville, MD, USA) for testing 
Staphylococcus spp. and Enterococcus spp.: Mueller-Hinton 
agar supplemented with 5% sheep blood for Streptococcus 
spp.; Brucella agar (Becton Dickinson) supplemented with 5 
μg/mL hemin, 1 μg/mL vitamin K1; and 5% laked sheep blood 
for anaerobic bacteria. Tedizolid and linezolid (Dong-A ST, 
Seoul, Korea); erythromycin, tetracycline, oxacillin and penicillin 
G (Sigma Chemical, St. Louis, MO, USA); piperacillin and tazo-
bactam (Yuhan, Seoul, Korea); clindamycin (Korea Upjohn, 
Seoul, Korea); levofloxacin (Daiichi Pharmaceutical, Tokyo, Ja-
pan); cefotetan (Daiichi Pharmaceutical); ampicillin and genta-
micin (Chong Kun Dang, Seoul, Korea); cefoxitin and imipenem 
(Merck Sharp & Dohme, Rahway, NJ, USA); meropenem (Sum-
itomo, Tokyo, Japan); metronidazole (ChoongWae, Seoul, Ko-
rea); trimethoprim and sulfamethoxazole (Dong Wha, Seoul, Ko-
rea); vancomycin (Daewoong, Seoul, Korea); and teicoplanin 
(Sanofi Aventis, Bridgewater, NJ, USA) were used as antimicro-
bial powders. American type culture collection strains of S. au-
reus (ATCC29213), E. faecalis (ATCC 29212), S. pneumoniae 
(ATCC 49619), Bacteroides fragilis (ATCC 25285), and B. the-
taiotaomicron (ATCC 29741) were used as reference strains. 
The non-meningeal breakpoints of penicillin G and cefotaxime 
were used for S. pneumoniae. This study used the breakpoints 
of tedizolid suggested by the US Food and Drug Administration 
[14].
 All of the aerobic and anaerobic gram-positive isolates in pa-
tients with SSSIs were inhibited by ≤1 μg/mL tedizolid (Table 1). 
The most potent drugs against MRSA were tedizolid (minimum 
inhibitory concentration [MIC]90 =0.5 μg/mL), linezolid (MIC90 =2 
μg/mL), and vancomycin (MIC90 =2 μg/mL). The MIC range of 
tedizolid was 0.125 to 0.5 μg/mL for MRSA, while that of line-
zolid was 0.25 to 4 μg/mL. The MIC90s of tedizolid were 0.5 μg/
mL for both MRSA and methicillin-susceptible S. aureus (MSSA) 
and ≤0.125 μg/mL for coagulase-negative staphylococci, which 
were 2- to 4-fold lower than those of linezolid. These MIC values 
were similar to those described in previous reports [10, 15]. The 
MICs of tedizolid were 0.25 μg/mL for all three vancomycin-in-
termediate S. aureus isolates.
 The MIC ranges of tedizolid were 0.25 to 0.5 μg/mL for En-
terococcus, while those of linezolid were 0.5 to 2 μg/mL. Te-
dizolid inhibited all vancomycin-resistant Enterococcus at 0.5 
μg/mL. When the meningeal breakpoint was applied, most of 
the pneumococcal isolates tested were not susceptible to peni-
cillin G or cefotaxime. However, the MIC range of tedizolid was 
0.25 to 1 μg/mL, and the MIC90 (0.5 μg/mL) was 4-fold lower 
than that of linezolid. Tedizolid inhibited all the isolates of viri-
dans Streptococcus spp. and β-hemolytic streptococci such as 
S. pyogenes and S. agalactiae at 0.5 μg/mL.
 Tedizolid had excellent activity against gram-positive anaer-
obes recovered from SSSIs (Table 1). The MIC ranges of tedizolid 
were 0.06 to 1 μg/mL for Finegoldia magna and ≤0.06 to 0.25 
μg/mL for the other Peptostreptococcus spp. The MIC90 values 
for these organisms were 0.5 and 0.25 μg/mL, respectively, 
which were 4-8 fold lower than those of linezolid. All the Clostrid-
ium spp. isolates were inhibited by tedizolid at 0.5 μg/mL.
 All the gram-positive isolates in patients with HAP were inhib-
ited by ≤0.5 μg/mL tedizolid (Table 2). The MIC ranges of te-
dizolid were 0.125 to 0.5 μg/mL for MRSA and 0.25 μg/mL for 
MSSA. The MIC90 values of tedizolid were 0.25, 0.5, and 0.5 μg/
mL for MSSA, MRSA, and pneumococci, respectively, which 
were 4- to 8-fold lower than those of linezolid. 
 In summary, the MIC values of tedizolid in this study were not 
significantly different according to type of infection. All organ-
isms tested were susceptible to tedizolid, nevertheless the 
breakpoint of tedizolid is 4- or 8-fold lower than that of linezolid. 
Tedizolid is a potent agent with high in vitro activity against com-
mon aerobic and anaerobic gram-positive pathogens in SSSIs 
and HAP. Tedizolid may become a useful option for the treat-
ment of SSSIs and HAP. 
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Table 1. Comparative in vitro activities of tedizolid and other antimicrobial agents against bacteria recovered from patients with skin and 
skin structure infections
Organism (N of isolates) 
   and antimicrobial agents
Breakpoint (µg/mL) MIC (µg/mL) Susceptibility (%)
S I R Range 50% 90% S I R
Methicillin-resistant Staphylococcus aureus (90)
   Tedizolid* ≤0.5 1 ≥2 0.125-0.5 0.5 0.5 100 0 0
   Linezolid ≤4 - ≥8 0.25-4 2 2 100 NA 0 
   Erythromycin   ≤0.5 1-4 ≥8 0.5->128 >128 >128 28 0 72 
   Clindamycin ≤0.5 1-2 ≥4 ≤0.06->128 >128 >128 44 0 56 
   Cotrimoxazole ≤2 - ≥4 ≤0.06-32 ≤0.06 0.125 98 NA 2 
   Gentamicin ≤4 8 ≥16 0.125->128 0.5 32 58 1 41 
   Levofloxacin ≤1 2 ≥4 0.25->128 16 >128 37 0 63 
   Tetracycline ≤4 8 ≥16 0.5->128 64 64 41 0 59 
   Oxacillin ≤2 - ≥4 8->128 >128 >128 0 NA 100 
   Vancomycin ≤2 4-8 ≥16 1-4 1 2 94 6 0 
Methicillin-susceptible S. aureus (90)
   Tedizolid ≤0.5 1 ≥2 ≤0.06-0.5 0.25 0.5 100 0 0
   Linezolid ≤4 - ≥8 0.25-2 2 2 100 NA 0 
   Erythromycin   ≤0.5 1-4 ≥8 0.25->128 0.5 >128 74 1 24 
   Clindamycin ≤0.5 1-2 ≥4 ≤0.06->128 0.125 0.125 99 0 1 
   Cotrimoxazole ≤2 - ≥4 ≤0.06-0.125 ≤0.06 0.125 100 NA 0
   Gentamicin ≤4 8 ≥16 0.125-128 0.25 32 82 1 17 
   Levofloxacin ≤1 2 ≥4 0.125-32 0.25 32 97 0 3 
   Tetracycline ≤4 8 ≥16 0.25-128 0.5 0.5 91 0 9 
   Oxacillin ≤2 - ≥4 ≤0.06-2 0.5 0.5 100 NA 0 
   Vancomycin ≤2 4-8 ≥16 1-2 1 1 100 0 0 
Coagulase-negative Staphylococcus (24)†
   Tedizolid NA NA NA ≤0.06-0.25 0.125 0.125 NA NA NA
   Linezolid ≤4 - ≥8 0.25-2 0.25 0.25 100 NA 0 
   Erythromycin ≤0.5 1-4 ≥8 ≤0.06->128 0.125 128 71 0 29
   Clindamycin ≤0.5 1-2 ≥4 ≤0.06->128 ≤0.06 0.125 96 0 4
   Cotrimoxazole ≤2 - ≥4 ≤0.06-4 ≤0.06 4 79 NA 21
   Gentamicin ≤4 8 ≥16 ≤0.06-128 0.125 16 50 21 29
   Levofloxacin ≤1 2 ≥4 ≤0.06-128 0.25 8 75 4 21
   Tetracycline ≤4 8 ≥16 0.125-128 0.25 64 75 0 25
   Oxacillin ≤0.25 - ≥0.5 0.125-128 0.5 2 38 NA 63
   Vancomycin ≤4 8-16 ≥32 1-2 2 2 100 0 0
Streptococcus pneumoniae (30)
   Tedizolid NA NA NA 0.25-1 0.25 0.5 NA NA NA
   Linezolid ≤2 - - 1-2 1 2 100 NA NA 
   Penicillin G ≤2 4 ≥8 0.06-4 4 4 27 73 0
   Cefotaxime ≤1 2 ≥4 0.06-2 2 2 27 73 0
(Continued to the next page)
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Organism (N of isolates) 
   and antimicrobial agents
Breakpoint (µg/mL) MIC (µg/mL) Susceptibility (%)
S I R Range 50% 90% S I R
   Clindamycin ≤0.25 0.5 ≥1 0.125->128 >128 >128   10 0   90
   Erythromycin ≤0.25 0.5 ≥1 8->128 >128 >128     0 0 100
   Cotrimoxazole ≤0.5 1-2 ≥4 0.5->128 32 64   13 0   87
   Levofloxacin ≤2 4 ≥8 2-8 2 4   87 10     3
   Tetracycline ≤1 2 ≥4 0.25-64 32 32     3 3   93
S. agalactiae (22)
   Tedizolid ≤0.5 - - 0.25-0.5 0.5 0.5 100 NA NA
   Linezolid ≤2 - - 2-4 2 2   96 NA NA 
   Penicillin G ≤0.12 - - 0.015-0.06 0.06 0.06 100 NA NA
   Cefotaxime ≤0.5 - - 0.015-0.06 0.06 0.06 100 NA NA
   Clindamycin ≤0.25 0.5 ≥1 0.125->128 0.125 >128   82 0 18
   Erythromycin ≤0.25 0.5 ≥1 0.125–>128 0.25 >128   77 0 23
   Levofloxacin ≤2 4 ≥8 1-64 2 64   59 9 32
   Tetracycline ≤2 4 ≥8 0.25-32 1 32   59 0 41
S. pyogenes (8)
   Tedizolid ≤0.5 - - 0.125-0.5 NA NA NA NA NA
   Linezolid ≤2 - - 1-2 NA NA NA NA NA
   Penicillin G ≤0.12 - - 0.015 NA NA NA NA NA
   Cefotaxime ≤0.5 - - 0.015-0.06 NA NA NA NA NA
   Clindamycin ≤0.25 0.5 ≥1 0.125->128 NA NA NA NA NA
   Erythromycin   ≤0.25 0.5 ≥1 0.25-32 NA NA NA NA NA
   Levofloxacin ≤2 4 ≥8 0.5-8 NA NA NA NA NA
   Tetracycline ≤2 4 ≥8 0.25-8 NA NA NA NA NA
Enterococcus faecalis (14)
   Tedizolid ≤0.5 - - 0.25-0.5 0.5 0.5 100 NA NA 
   Linezolid ≤2 4 ≥8 1-2 2 2 100 0 0 
   Ampicillin ≤8 - ≥16 0.5-4 1 4 100 NA 0 
   Erythromycin ≤0.5 1-4 ≥8 0.5->128 >128 >128     0 36 64 
   Levofloxacin ≤2 4 ≥8 1->128 1 128   64 0 36 
   Tetracycline ≤4 8 ≥16 0.5->128 64 128   14 0 86 
   Teicoplanin ≤8 16 ≥32 ≤0.06-1 0.5 1 100 0 0 
   Vancomycin ≤4 8-16 ≥32 0.5-4 1 2 100 0 0 
E. faecium (16)
   Tedizolid NA NA NA 0.25-0.5 0.25 0.25 NA NA NA
   Linezolid ≤2 4 ≥8 0.5-2 2 2 100 0 0 
   Ampicillin ≤8 - ≥16 16->128 64 128     0 NA 100 
   Erythromycin ≤0.5 1-4 ≥8 ≤0.06->128 >128 >128     6 0   94 
   Levofloxacin ≤2 4 ≥8 32-128 128 128     0 0 100 
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Organism (N of isolates) 
   and antimicrobial agents
Breakpoint (µg/mL) MIC (µg/mL) Susceptibility (%)
S I R Range 50% 90% S I R
   Tetracycline ≤4 8 ≥16 0.25-128 0.5 128 56 0 44 
   Vancomycin ≤4 8-16 ≥32 1->128 1 >128   56 0 44 
   Teicoplanin ≤8 16 ≥32 0.25-128 1 32   56 19 25 
Viridans group Streptococcus spp. (10)‡
   Tedizolid NA NA NA 0.25-0.5 0.25 0.25 NA NA NA
   Linezolid ≤2 - - 1-2 1 2 100 NA NA
   Penicillin G ≤0.12 0.25-2 ≥4 0.03-2 0.06 0.5   70 10 0 
   Cefotaxime ≤1 2 ≥4 0.06-2 0.25 1   90 10 0 
   Clindamycin ≤0.25 0.5 ≥1 ≤0.06->128 0.125 >128   60 0 40 
   Erythromycin ≤0.25 0.5 ≥1 ≤0.06->128 0.125 128   50 10 40 
   Levofloxacin ≤2 4 ≥8 0.5-2 1 2 100 0 0 
   Tetracycline ≤2 4 ≥8 0.25-64 16 64   40 0 60 
Finegoldia magna (21)
   Tedizolid NA NA NA 0.06-1 0.25 0.5 NA NA NA
   Linezolid NA NA NA 0.5-2 2 2 NA NA NA
   Piperacillin ≤32 64 ≥128 ≤0.06-0.25 0.125 0.25 100 0 0
   Pip/tazobactam ≤32 64 ≥128 ≤0.06-0.25 ≤0.06 0.125 100 0 0
   Cefoxitin ≤16 32 ≥64 0.125-2 1 1 100 0 0
   Cefotetan ≤16 32 ≥64 0.25-2 1 2 100 0 0
   Imipenem ≤4 8 ≥16 ≤0.06-0.125 ≤0.06 0.125 100 0 0
   Clindamycin ≤2 4 ≥8 ≤0.06->128 2 >128   55 9 36
   Metronidazole ≤8 16 ≥32 0.25-4 1 2 100 0 0
   Vancomycin NA NA NA 0.25-1 0.25 0.5 NA NA NA
Peptostreptococcus spp. (27)§
   Tedizolid NA NA NA ≤0.06-0.25 0.125 0.25 NA NA NA
   Linezolid NA NA NA 0.5-2 1 2 NA NA NA
   Piperacillin ≤32 64 ≥128 ≤0.06-1 ≤0.06 1 100 0 0
   Pip/tazobactam ≤32 64 ≥128 ≤0.06-1 ≤0.06 0.25 100 0 0
   Cefoxitin ≤16 32 ≥64 ≤0.06-8 0.5 4 100 0 0
   Cefotetan ≤16 32 ≥64 0.125-8 0.5 2 100 0 0
   Imipenem ≤4 8 ≥16 ≤0.06-0.5 ≤0.06 0.125 100 0 0
   Clindamycin ≤2 4 ≥8 ≤0.06-128 0.25 128   74 4 22
   Metronidazole ≤8 16 ≥32 0.5-2 1 2 100 0 0
   Vancomycin NA NA NA 0.125-1 0.25 1 NA NA NA
Clostridium spp. (4)||
   Tedizolid NA NA NA 0.25-0.5 NA NA NA NA NA
   Linezolid NA NA NA 2-4 NA NA NA NA NA
   Piperacillin ≤32 64 ≥128 0.25-2 NA NA NA NA NA
(Continued to the next page)
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Organism (N of isolates) 
   and antimicrobial agents
Breakpoint (µg/mL) MIC (µg/mL) Susceptibility (%)
S I R Range 50% 90% S I R
   Pip/tazobactam ≤32 64 ≥128 0.125-2 NA NA NA NA NA
   Cefoxitin ≤16 32 ≥64 4-32 NA NA NA NA NA
   Cefotetan ≤16 32 ≥64 0.25-2 NA NA NA NA NA
   Imipenem ≤4   8 ≥16 0.25-2 NA NA NA NA NA
   Clindamycin ≤2   4 ≥8 0.125->128 NA NA NA NA NA
   Metronidazole ≤8 16 ≥32 0.5-8 NA NA NA NA NA
   Vancomycin NA NA NA 0.5-4 NA NA NA NA NA
*FDA breakpoints were used for tedizolid; †Staphylococcus epidermidis (N=22), S. caprae (N=1), S. warneri (N=1); ‡Streptococcus mitis (N=6), S. angi-
nosus (N=2), S. constellatus (N=2); §P. asaccharolyticus (N=11), P. micros (N=7), Anaerococcus prevotii (N=8), P. anaerobius (N=1); ||C. perfringens 
(N=2), C. ramosum (N=2).
Abbreviations: MIC, minimum inhibitory concentration; S, susceptible; I, intermediate; R, resistant; NA, not available/applicable; Pip/tazobactam, piperacillin/
tazobactam.
Table 1. Continued
Table 2. Comparative in vitro activities of tedizolid and other antimicrobial agents against bacteria recovered from patients with hospital-ac-
quired pneumonia
Organism (N of isolates) and 
   antimicrobial agents
Breakpoint (µg/mL) MIC (µg/mL) Susceptibility (%)
S I R Range 50% 90% S I R
Methicillin-resistant Staphylococcus aureus (61)
   Tedizolid* ≤0.5 1 ≥2 0.125-0.5 0.25 0.5 100 0     0 
   Linezolid ≤4 - ≥8 1-2 2 2 100 NA     0 
   Erythromycin ≤0.5 1-4 ≥8 0.25->128 >128 >128   10 0    90 
   Clindamycin ≤0.5 1-2 ≥4 ≤0.06->128 >128 >128   23 0    77 
   Cotrimoxazole ≤2 - ≥4 ≤0.06-4 ≤0.06 0.125   98 NA     2 
   Gentamicin ≤4 8 ≥16 0.125-128 32 64   38 0   62 
   Levofloxacin ≤1 2 ≥4 0.25->128 32 32   16 0   84 
   Tetracycline ≤4 8 ≥16 0.25-128 128 128   18 0   82 
   Oxacillin ≤2 - ≥4 32->128 >128 >128    0 NA 100 
   Vancomycin ≤2 4-8 ≥16 0.5-2 1 2 100 0     0 
Methicillin-susceptible S. aureus (28)
   Tedizolid ≤0.5 1 ≥2 0.25-0.25 0.25 0.25 100 0 0 
   Linezolid ≤4 - ≥8 1-2 2 2 100 NA 0 
   Erythromycin ≤0.5 1-4 ≥8 0.25->128 0.25 0.25   93 4 4 
   Clindamycin ≤0.5 1-2 ≥4 ≤0.06-64 ≤0.06 ≤0.06   93 4 4 
   Cotrimoxazole ≤2 - ≥4 ≤0.06-0.25 ≤0.06 ≤0.06 100 NA 0 
   Gentamicin ≤4 8 ≥16 0.125-16 0.25 0.25   96 0 4 
   Levofloxacin ≤1 2 ≥4 0.125-8 0.25 1   93 0 7 
   Tetracycline ≤4 8 ≥16 0.25-0.25 0.25 0.25 100 0 0 
   Oxacillin ≤2 - ≥4 0.125-0.5 0.25 0.5 100 NA 0 
   Vancomycin ≤2 4-8 ≥16 1-2 1 1 100 0 0 
(Continued to the next page)
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Organism (N of isolates) and 
   antimicrobial agents
Breakpoint (µg/mL) MIC (µg/mL) Susceptibility (%)
S I R Range 50% 90% S I R
S. epidermidis (8)
   Tedizolid NA NA NA ≤0.06 NA NA NA NA NA
   Linezolid ≤4 - ≥8 0.25 NA NA NA NA NA
   Erythromycin ≤0.5 1-4 ≥8 ≤0.06-128 NA NA NA NA NA
   Clindamycin ≤0.5 1-2 ≥4 ≤0.06->128 NA NA NA NA NA
   Cotrimoxazole ≤2 - ≥4 ≤0.06-4 NA NA NA NA NA
   Gentamicin ≤4 8 ≥16 ≤0.06-128 NA NA NA NA NA
   Levofloxacin ≤1 2 ≥4 4-128 NA NA NA NA NA
   Tetracycline   ≤4 8 ≥16 0.125-32 NA NA NA NA NA
   Oxacillin ≤0.25 - ≥0.5 0.5-32 NA NA NA NA NA
   Vancomycin ≤4 8-16 ≥32 1-2 NA NA NA NA NA
Streptococcus pneumoniae (47)
   Tedizolid NA NA NA 0.25-0.5 0.25 0.5 NA NA NA
   Linezolid ≤2 - - 1-2 1 2 100 NA NA 
   Penicillin G ≤2 4 ≥8 0.015-8 2 8   49 28 23
   Cefotaxime ≤1 2 ≥4 0.015-32 1 32   55 26 19
   Clindamycin ≤0.25 0.5 ≥1 0.125->128 >128 >128   15 0 85 
   Erythromycin ≤0.25 0.5 ≥1 0.25->128 >128 >128   6   0 94 
   Cotrimoxazole ≤0.5 1-2 ≥4 1-32 8 32 23 15 62 
   Levofloxacin ≤2 4 ≥8 2-128 2 32 72   2 26 
   Tetracycline   ≤1 2 ≥4 0.25-128 32 64 13   0 87 
*FDA breakpoints were used for tedizolid.
Abbreviations: MIC, minimum inhibitory concentration; S, susceptible; I, intermediate; R, resistant; NA, not available/applicable; Pip/tazobactam, piperacillin/
tazobactam.
Table 2. Continued
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